Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04PLI
|
|||
| Former ID |
DCL000999
|
|||
| Drug Name |
SR46349B
|
|||
| Synonyms |
Eplivanserin fumarate; SR 46349; SR 46349B; SR-46349B; 2-Propen-1-one, 1-(2-fluorophenyl)-3-(4-hydroxyphenyl)-, O-(2-(dimethylamino)ethyl)oxime, (Z,E)-, (E)-2-butenedioate (2:1) (salt); 4-((3Z)-3-(2-Dimethylaminoethyl)oxyimino-3-(2-fluorophenyl)propen-1-yl)phenol hemifumarate; 4-[(E)-3-(2-dimethylaminoethyloxyamino)-3-(2-fluorophenyl)prop-2-enylidene]cyclohexa-2,5-dien-1-one
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Primary insomnia [ICD-11: 7A00; ICD-10: F51.0] | Phase 3 | [1] | |
| Schizophrenia [ICD-11: 6A20] | Phase 3 | [1] | ||
| Sleep-wake disorder [ICD-11: 7A00-7B2Z] | Phase 3 | [1] | ||
| Company |
Sanofi-Aventis
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C42H46F2N4O8
|
|||
| Canonical SMILES |
CN(C)CCON=C(C=CC1=CC=C(C=C1)O)C2=CC=CC=C2F.CN(C)CCON=C(C=CC1=CC=C(C=C1)O)C2=CC=CC=C2F.C(=CC(=O)O)C(=O)O
|
|||
| InChI |
1S/2C19H21FN2O2.C4H4O4/c2*1-22(2)13-14-24-21-19(17-5-3-4-6-18(17)20)12-9-15-7-10-16(23)11-8-15;5-3(6)1-2-4(7)8/h2*3-12,23H,13-14H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b2*12-9+,21-19-;2-1+
|
|||
| InChIKey |
RNLKLYQQDLHHBH-ABDBJYMXSA-N
|
|||
| CAS Number |
CAS 130580-02-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | 5-HT 2A receptor (HTR2A) | Target Info | Modulator | [2] |
| 5-HT 2C receptor (HTR2C) | Target Info | Modulator | [2] | |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Gap junction | ||||
| Serotonergic synapse | ||||
| Inflammatory mediator regulation of TRP channels | ||||
| Panther Pathway | 5HT2 type receptor mediated signaling pathway | |||
| Reactome | Serotonin receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | Serotonin Receptor 2 and STAT3 Signaling | |||
| Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | ||||
| SIDS Susceptibility Pathways | ||||
| Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. | |||
| REF 2 | SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsychopharmacology. 2002 Sep;27(3):430-41. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.